That makes PANC even more interesting with angle that Roche could preempt move by TRMS or vice-versa. Thanks for that thought - I had been hearing of squabbles elsewhere also. What I find amusing is that PANC has halved (or so) as their drugs continue to advance. Of course losing the head of the company from a heart attack at a healthcare conference . . .
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.